NCT05821387View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

July 29, 2023

Study Completion Date

July 29, 2023

Conditions

Healthy Participants

Interventions

DRUG

Lucid-21-302

A small molecule inhibitor of hypercitrullination

DRUG

Placebo

Product containing excipients with no active ingredients

Trial Locations (1)

M9L 3A2

Biopharma Services Incorporated, Toronto

Sponsors

Lead Sponsor

Quantum Biopharma

All Listed Sponsors

collaborator

Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.)

UNKNOWN

lead

Quantum Biopharma

INDUSTRY

NCT05821387 - Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers | Biotech Hunter | Biotech Hunter